2SEVENTY BIO, INC. - Annual Financials - Income Statement (SEC)

Updated on January 2, 2026.

Related Topics: SEC Topic List.

Data Source: SEC.

See details in table below.

You can see similar for other companies.

2SEVENTY BIO, INC. - Annual Income Statement (In Thousands of USD, Except Per Share Amounts)

Breakdown	2024-12-31	2023-12-31
Collaborative arrangement revenue	19744	71601
Total revenues	37862	100387
Research and development	76917	230758
Cost of manufacturing for commercial collaboration	18010	14819
Selling, general and administrative	43924	69414
Share of collaboration loss	-4553	0
Restructuring expenses	12303	8614
Cost of royalty and other revenue	0	2099
Change in fair value of contingent consideration	-2415	235
Goodwill impairment charge	0	12056
Total operating expenses	153292	337995
Loss from operations	-115430	-237608
Interest income, net	10875	12413
Other income, net	4347	7625
Loss before income taxes	-57247	-217570
Income tax expense	0	0
Net loss	-57247	-217570
Basic Earnings Per Share	-1.1	-4.42
Diluted Earnings Per Share	-1.1	-4.42
Basic Weighted Average Shares Outstanding	52218	49276
Diluted Weighted Average Shares Outstanding	52218	49276
Other comprehensive income, net of tax benefit (expense) of $0.0 million and $0.0 million for the years ended December 31, 2024 and 2023, respectively.	293	2673
Comprehensive loss	-56954	-214897
Other comprehensive income (loss), net of tax benefit (expense)	0	0